PPT-Update on Genetics in Hypertension

Christian Delles BHF Glasgow Cardiovascular Research Centre Institute of Cardiovascular and Medical Sciences University of Glasgow Cardiovascular Continuum Twin studies pedigree studies BP variability attributable to all genetic factors . Weber MD Ernesto L Schiffrin MD William B White MD Samuel Mann MD Lars H Lindholm MD John G Kenerson MD John M Flack MD Barry L Carter Pharm D Barry J Materson MD C Venkata S Ram MD 10 Debbie L Cohen MD 11 JeanClaude Cadet MD 12 Roger R JeanCharles CHAPTER Hypertension and the Kidney Adrenal Hypertension PHYSIOLOGIC MECHANISMS IN ADRENAL HYPERTENSION DisorderPrimary aldosteronismCushing Andy Saykin. WW-ADNI Meeting. London, UK. July 14, 2017. asaykin@iupui.edu. Overview and 2017 Updates. ADNI-3 sample collection (banked at NCRAD). Longitudinal DNA & RNA (12 new, 79 continuing). Changes in ADNI-3 include PBMC and RBC collection. Claude K. Lardinois, MD, FACP, MACN, FACE. lardinois@sbcglobal.net. . . Emeritus Professor. University of Nevada School of Medicine, Reno, Nevada. Board Certified Endocrinologist. Medical Director for American Health Care, Rocklin, CA. ACCF/AHA 2011. Expert Consensus Document. . . Developed in collaboration with the American Academy of Neurology, Association of Black Cardiologists, American Geriatrics Society, American Society of Hypertension, American Society of Nephrology, American Society for Preventive Cardiology, and the European Society of Hypertension. Classification (. A. dults). BP Classification. Systolic BP (mmHg). Diastolic BP (mmHg). Normal. < 120. and <. 80. Prehypertension. 120 – 139. or 80 - 89. Stage 1 hypertension. Circulation 2014;129:587-597. Teaching Tool: Hyperfiltration Early Sign of Hypertension and Diabetes. J Am Soc Nephrol 2017;28:1023-1039. Hyperfiltration Early in . Diabetic Nephropathy. Circulation 2016;134:752-772. Jessica Schwenk, Pharm.D.. September 14, 2013. Objectives. Review pharmacologic treatment of hypertension, including drug combinations and management of hypertension with other disease states. Discuss updates in the use of antihypertensive drugs. Worldwide-ADNI Update Meeting. Friday, July 22, 2016. Fairmont Royal York . Hotel. Toronto. Andy Saykin, . Indiana University. For the Genetics Core/Working Groups. asaykin@iupui.edu. Genetics Core Goals for ADNI-3. WW-ADNI Meeting, Washington DC. July 17, 2015. Andy Saykin, . Indiana University. asaykin@iupui.edu. For the Genetics Core/Working Groups. Original ADNI-2 Specific Aims. Progress Report & Impact. Hypertension . doubles the risk of cardiovascular diseases, including coronary heart disease (CHD), congestive heart failure (CHF), ischemic and hemorrhagic stroke, renal failure, and peripheral arterial disease. Samir Mustafa Smisim Medical Director Of training Dept SRCA, Saudi Arabia Abstract: Introduction: Gestational Hypertension can lead to a serious con - Preeclampsia,referredtoToxemia.Hyperten - sion d Peter Julian A. Francisco, MD, DFM. Clinical Associate Professor UPCM – Department of Family and Community Medicine. Professional Member, International Society of Hypertension. EPIDEMIOLOGY. The global prevalence of hypertension is high. In 2000 it is suggested that approximately 26 % of the total population had hypertension. (Kearney, PM et al. Lancet 2005).. Lead Speaker: Dr Tarek Antonios. Ambra Caruso, Kristina . Leonnet. and Dr Roy Jogiya. Today:. 2. Welcome and Reminders – Ambra Caruso. National Blood Pressure Programme – Kristina . Leonnet. Hypertension Webinar – Dr Tarek Antonios.